Xuerong Biology: 2024 Semi-Annual Report
Xuerong Biology: 2024 Semi-Annual Report Summary
Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) Stock Catapults 45% Though Its Price And Business Still Lag The Industry
Shanghai Xuerong Bio-Technology (300511.SZ): Intends to repurchase 31.03% equity of Lin Tao Xuerong held by the fund.
On August 5th, Gelunhui reported that Shanghai Xuerong Bio-technology (300511.SZ) held the 12th meeting of the fifth board of directors on August 5, 2024, and passed the Proposal on Repurchasing the Equity of Subsidiaries with 6 votes in favor, 0 votes against and 0 abstentions. According to the arrangements for equity repurchase stipulated in the capital increase and share expansion agreement, the company and Linchuan Xuerong, along with Gansu Industrial Development Investment Fund Co., Ltd. (hereinafter referred to as 'Investment Fund'), signed the 'Agreement on Repurchase and Share Transfer of Linchuan Xuerong Bio-technology Co., Ltd.'s Held by Investment Fund' on August 5th, 2024, with the company repurchasing Linchuan Xuerong held by Investment Fund.
Xuerong Biology (300511.SZ): In 2023, the production of enoki mushrooms was 366,700 tons, and the production of shimeji mushrooms was 81,700 tons
Shanghai Xuerong Bio-Technology (300511.SZ) stated on the investor communication platform that the company's main raw materials include rice bran, corn cob, bran, cottonseed hulls, beer dregs, etc. The company's suppliers are widely distributed and numerous, and there is no reliance on a single supplier. In 2023, the company's production of shiitake mushrooms was 366,700 tons, and the production of enoki mushrooms was 81,700 tons.
Shanghai Xuerong Bio-technology (300511.SZ): focuses on the research and development, factory production, and sales of fresh edible mushrooms.
Shanghai Xuerong Bio-Technology (300511.SZ) stated on the investor interaction platform on June 7th that the company's main business is the research and development, factory cultivation, and sales of fresh edible mushrooms. The company's products are mainly sold through dealers and directly sold to channels such as supermarket systems, chain dining systems, and fresh delivery platforms. The company will continue to actively develop domestic and foreign markets.
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Even After Rising 31% This Past Week, Shanghai Xuerong BiotechnologyLtd (SZSE:300511) Shareholders Are Still Down 50% Over the Past Five Years
Xuerong Biotech (300511.SZ) reported first-quarter results, net profit of 5.2403 million yuan, a year-on-year decrease of 97.65%
Xuerong Biotech (300511.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Xuerong Biotech (300511.SZ) holds 1.96% shareholder Zhu Huancheng plans to liquidate and reduce holdings
Xuerong Biology (300511.SZ) announced that Zhu Huancheng, a specific shareholder of the company, plans to make three transactions from the date of publication of this announcement...
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Xuerong Biology (300511.SZ)'s edible fungus products are generally sold around production bases, radiating surrounding areas
Gelonghui March 19 | Xuerong Biotech (300511.SZ) said on the investor interactive platform that the company currently has eight major domestic production bases: Changchun, Jilin, Dezhou, Guangdong, Dujiangyan, Sichuan, Bijie, Guizhou, Linyi, Gansu, Guigang, Guangxi, and Huai'an, Jiangsu. The company's edible fungus products are generally sold around production bases and surrounding areas.
Xuerong Biotech (300511.SZ): Plans to use capital raising related claims to increase capital for wholly-owned subsidiaries
Gelonghui, Feb. 23, 丨 Xuerong Biotech (300511.SZ) announced that the company increased its capital at RMB 1 yuan/share through debt-for-share swaps of 170 million yuan in part of the debt raised against its wholly-owned subsidiary Guangxi Xuerong Biotechnology Co., Ltd. (“Guangxi Xuerong”). After the capital increase is completed, the registered capital of Guangxi Xuerong will increase from 10 million yuan to 270 million yuan, and it is still a wholly-owned subsidiary of the company.
Revenues Working Against Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Share Price Following 26% Dive
Xuerong Biotech (300511.SZ) and related personnel accepted the Shanghai Securities Regulatory Bureau's administrative supervision measures decision
Xuerong Biotech (300511.SZ) issued an announcement. The company received the Shanghai Securities Regulatory Bureau on December 25, 2023...
Xuerong Biotech (300511.SZ): Net loss of 169 million yuan in the third quarter
On October 27, Gelonghui Biotech (300511.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 569 million yuan, a year-on-year decrease of 15.86%; net profit attributable to shareholders of listed companies was -169 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -172 million yuan; and basic earnings per share was -0.34 yuan.
Returns On Capital Are Showing Encouraging Signs At Shanghai Xuerong BiotechnologyLtd (SZSE:300511)
Xuerong Biotech (300511.SZ): The controlling shareholder's concerted action has reduced its holdings by 0.67% at the end of Yinwan Huayi's holdings reduction of No. 1
GLONGHUI, August 14丨Xuerong Biotech (300511.SZ) announced that the company recently received a “Notice Concerning the Expiration of the Stock Holding Reduction Plan” issued by Yinwan Huayi No. 1, co-actor of Mr. Yang Yongping, the controlling shareholder of the company. As of August 13, 2023, the term of Yinwan Huayi No. 1's holdings reduction plan has expired. It reduced its holdings by a total of 3.3654 million shares, a change ratio of 0.67%.
Zhu Huancheng, a shareholder of Xuerong Biotech (300511.SZ), reduced his holdings by a total of 3.257 million shares at the end of the holdings reduction period
According to the Zhitong Finance App, Xuerong Biotech (300511.SZ) announced that the term of the company's shareholder Zhu Huancheng's holdings reduction plan has expired, reducing the company's holdings by a total of 3.257 million shares.
A Look At The Fair Value Of Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511)
No Data
No Data